MA32468B1 - Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k - Google Patents

Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k

Info

Publication number
MA32468B1
MA32468B1 MA33511A MA33511A MA32468B1 MA 32468 B1 MA32468 B1 MA 32468B1 MA 33511 A MA33511 A MA 33511A MA 33511 A MA33511 A MA 33511A MA 32468 B1 MA32468 B1 MA 32468B1
Authority
MA
Morocco
Prior art keywords
thiophene
pi3k inhibitors
thiazole derivatives
compounds
pi3k
Prior art date
Application number
MA33511A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32468(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA32468B1 publication Critical patent/MA32468B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA33511A 2008-06-19 2011-01-13 Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k MA32468B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (en) 2008-06-19 2009-06-17 Thiophene or thiazole derivatives and their use as pi3k inhibitors

Publications (1)

Publication Number Publication Date
MA32468B1 true MA32468B1 (fr) 2011-07-03

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33511A MA32468B1 (fr) 2008-06-19 2011-01-13 Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k

Country Status (21)

Country Link
US (3) US8183240B2 (enExample)
EP (1) EP2313399B1 (enExample)
JP (1) JP5596026B2 (enExample)
KR (1) KR20110018451A (enExample)
CN (1) CN102066365A (enExample)
AU (1) AU2009260782B2 (enExample)
BR (1) BRPI0914223A2 (enExample)
CA (1) CA2727069A1 (enExample)
CL (1) CL2010001474A1 (enExample)
CO (1) CO6331431A2 (enExample)
CR (1) CR20110032A (enExample)
EA (1) EA201170052A1 (enExample)
ES (1) ES2491522T3 (enExample)
GE (1) GEP20125650B (enExample)
IL (1) IL210055A0 (enExample)
MA (1) MA32468B1 (enExample)
MX (1) MX2010014125A (enExample)
NZ (1) NZ589844A (enExample)
UA (1) UA106206C2 (enExample)
WO (1) WO2009154741A1 (enExample)
ZA (1) ZA201008875B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
KR20110018451A (ko) * 2008-06-19 2011-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 티오펜 또는 티아졸 유도체, 그리고 ｐｉ3ｋ 저해물질로서 이들의 용도
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2391619A1 (en) * 2009-01-30 2011-12-07 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG10201506238SA (en) 2010-08-11 2015-09-29 Millennium Pharm Inc Heteroaryls And Uses Thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
PL2790705T3 (pl) 2011-12-15 2018-06-29 Novartis Ag Zastosowanie inhibitorów czynności lub funkcji PI3K
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP6329936B2 (ja) * 2012-03-14 2018-05-23 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルス腫瘍診断
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
JP2017505787A (ja) * 2014-02-14 2017-02-23 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療薬としてのヒトアンドロゲン受容体ｄｎａ結合ドメイン（ｄｂｄ）化合物およびそれらを使用する方法
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
JP7498199B2 (ja) * 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
MX2022007665A (es) 2019-12-20 2022-07-19 Bayer Ag Tiofenocarboxamidas sustituidas y sus derivados.
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
CN101484452A (zh) 2006-05-03 2009-07-15 阿斯利康(瑞典)有限公司 噻唑衍生物及其作为抗肿瘤药物的用途
AU2007287428B2 (en) * 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
KR20110018451A (ko) * 2008-06-19 2011-02-23 밀레니엄 파머슈티컬스 인코퍼레이티드 티오펜 또는 티아졸 유도체, 그리고 ｐｉ3ｋ 저해물질로서 이들의 용도

Also Published As

Publication number Publication date
CA2727069A1 (en) 2009-12-23
EP2313399B1 (en) 2014-05-28
US8440664B2 (en) 2013-05-14
GEP20125650B (en) 2012-09-25
AU2009260782A1 (en) 2009-12-23
US20120202812A1 (en) 2012-08-09
US20130217689A1 (en) 2013-08-22
US20100075951A1 (en) 2010-03-25
BRPI0914223A2 (pt) 2019-09-24
EP2313399A1 (en) 2011-04-27
JP2011524904A (ja) 2011-09-08
EA201170052A1 (ru) 2011-06-30
JP5596026B2 (ja) 2014-09-24
UA106206C2 (ru) 2014-08-11
NZ589844A (en) 2012-11-30
CO6331431A2 (es) 2011-10-20
IL210055A0 (en) 2011-02-28
WO2009154741A8 (en) 2010-03-25
CR20110032A (es) 2011-03-14
MX2010014125A (es) 2011-02-24
CL2010001474A1 (es) 2011-04-29
KR20110018451A (ko) 2011-02-23
CN102066365A (zh) 2011-05-18
ZA201008875B (en) 2012-02-29
US8183240B2 (en) 2012-05-22
WO2009154741A1 (en) 2009-12-23
ES2491522T3 (es) 2014-09-08
AU2009260782B2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA32231B1 (fr) Composés organiques
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA34797B1 (fr) Hétéroaryles et leurs utilisations
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MA32171B1 (fr) Compose heterocyclique
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
WO2008036652A3 (en) Amidines as modulators of indoleamine 2,3-dioxygenase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
EA201000098A1 (ru) Производные хиназолинамида
EP2331520A4 (en) ROSAMINE DERIVATIVES AS AGENTS FOR CANCER TREATMENT
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c